Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Apazunersen · GTX-102

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: UBE3A-ATS (UBE3A antisense transcript) · developed by Ultragenyx Pharmaceutical

Phase 3 Most advanced trial (none active)
RARE Developer
1 Registered trials

What is Apazunersen?

Apazunersen (GTX-102) is an antisense oligonucleotide given as an oral spray and studied in Angelman syndrome and ataxia telangiectasia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GTX-102
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
UBE3A-ATS (UBE3A antisense transcript)
Mechanism
Gene silencing: UBE3A-ATS (UBE3A antisense transcript)
Therapy area
Neurology
Developer
Ultragenyx Pharmaceutical Inc (RARE)
Also in trials of
GRCE
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
ABG25J5B9G

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06617429 Phase 3 Angelman Syndrome Terminated RARE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Angelman SyndromeAtaxia Telangiectasia

More from Ultragenyx Pharmaceutical

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the RARE page.

Follow RARE, the company behind Apazunersen

See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RARE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.